In order to accelerate the generation of leads Aventis Pharma has constructed large biased libraries of chemical compounds. By using automated synthesis and parallel synthesis for the creation of new chemical entities, productivity in synthetic organic synthesis has increased by almost 600 percent. While in the past it took on average 46 months to move from exploratory research to an early development compound, today at Aventis Pharma this time has already decreased to 30 months on average. New pipeline products will drive growth in vaccine business Alf Lindberg presented the pipeline of new products under development of Aventis Pasteur. Vaccine combinations are a key component of the Aventis Pasteur portfolio.
Combination vaccines can protect children against multiple diseases with only one injection.
The specific vaccine combination can be adapted to meet geographical and age needs. Aventis Pasteur is currently in phase II trials with candidate vaccines for prophylaxis against HIV type 1 and is also working on a therapeutic vaccine for AIDS patients as a complement to triple drug therapies. In-house resources are enhanced by a large number of active collaborations. We are sharing the masses of knowledge we now have more efficiently. As a result we can quickly focus our resources on driving those products that will make a difference to our patients and our company.